Press release content from Business Wire. The AP news staff was not involved in its creation.
JCRI-ABTS and USMI Successfully Use Canady Helios™ Cold Plasma in Combination with FOLFIRINOX for the Treatment of Cholangiocarcinoma
April 28, 2021 GMT
TAKOMA PARK, Md. (BUSINESS WIRE) Apr 28, 2021
ADVERTISEMENT
Authors on the paper were Olivia Jones, BS (JCRI-ABTS), Xiaoqian Cheng, PhD (JCRI-ABTS), Saravana R.K. Murthy, PhD (JCRI-ABTS), Lawan Ly, BS (JCRI-ABTS), Taisen Zhuang, PhD (USMI), Giacomo Basadonna, MD/PhD (Department of Surgery, University of Massachusetts School of Medicine), Michael Keidar, PhD (School of Engineering and Applied Science, The George Washington University) and Jerome Canady, MD (JCRI-ABTS/GWU).
System4 Technologies GmbH: Universal Therapy Device For COVID-19, COVID-19 Mutations, and Other Virus Variants Unveiled
Possible use in intensive care medicine and treatment of long COVID.
Planned large-scale study on universal use against coronaviruses and other RNA viruses.
BAD ZWISCHENAHN, GERMANY / ACCESSWIRE / April 21, 2021 / The life science company System4 Technologies GmbH has developed a new therapy device for the treatment of Covid patients.
The device, named PI-RNA, is designed to enable universal and fast deactivation of coronaviruses and influenza viruses, their mutations and new variants by means of
a special cold atmospheric plasma procedure. The so-called CAP (Cold Atmospheric Plasma) - technology transfers electrostatically atmospheric anions, in high numbers and densities, into and around the body of the patient. This is achieved through a
Initial off-label-use applications with a special plasma design are promising. Possible use in intensive care medicine and treatment of long COVID. Planned large-scale study on universal use against coronaviruses and other RNA viruses. The life science company System4 Technologies GmbH has developed a new therapy device for the treatment of Covid patients. The device, named PI-RNA, is designed to enable universal and fast deactivation of coronaviruses and influenza viruses, their mutations and new variants by means of a special cold atmospheric plasma procedure. The so-called CAP (Cold Atmospheric Plasma) - technology transfers electrostatically atmospheric anions, in high numbers and densities, into and around
DGAP-Media / 21.04.2021 / 09:30 Initial off-label-use applications with a special plasma design are promising. Possible use in intensive care medicine and treatment of long COVID. Planned large-scale study on universal use against coronaviruses and other RNA viruses. The life science company System4 Technologies GmbH has developed a new therapy device for the treatment of Covid patients.
The device, named PI-RNA, is designed to enable universal and fast deactivation of coronaviruses and influenza viruses, their mutations and new variants by means of
a special cold atmospheric plasma procedure. The so-called CAP (Cold Atmospheric Plasma) - technology transfers electrostatically atmospheric anions, in high numbers and densities, into and around the body of the patient. This is achieved through a